August 23, 2017 – By Vivian Park
Wall Street await Pharma Bio Serv Inc (OTCMKTS:PBSV) to release earnings on September, 13. Analysts forecast earnings per share of $-0.01, exactly $0.00 or 0.00 % from 2014’s $-0.01 EPS. After posting $-0.01 EPS for the previous quarter, Pharma Bio Serv Inc’s analysts now forecast 0.00 % EPS growth. It is down 0.00% since August 23, 2016 and is . It has underperformed by 16.70% the S&P500.
Pharma-Bio Serv, Inc. is a compliance and technology transfer services consulting company. The company has market cap of $15.59 million. The Firm operates through four divisions: Puerto Rico technical compliance consulting, United States technical compliance consulting, Europe technical compliance consulting, and Puerto Rico microbiological and chemical laboratory testing division . It currently has negative earnings. The Firm provides a range of compliance-related consulting services.
More news for Pharma Bio Serv Inc (OTCMKTS:PBSV) were recently published by: Marketwired.com, which released: “Pharma-Bio Serv Signs Strategic Collaboration Agreement With Quality Technical …” on October 09, 2014. Seekingalpha.com‘s article titled: “What Is Pharma-Bio Serv’s Goal With An M&A Advisor?” and published on November 20, 2015 is yet another important article.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.